Last reviewed · How we verify
IL2
IL-2 (interleukin-2) is a cytokine that activates and expands T cells and natural killer cells to enhance anti-tumor immune responses.
IL-2 (interleukin-2) is a cytokine that activates and expands T cells and natural killer cells to enhance anti-tumor immune responses. Used for Metastatic melanoma, Metastatic renal cell carcinoma.
At a glance
| Generic name | IL2 |
|---|---|
| Also known as | Interleukin, Interleukin-2 |
| Sponsor | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
| Drug class | Cytokine immunotherapy |
| Target | IL-2 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IL-2 binds to IL-2 receptors on lymphocytes, promoting their proliferation, differentiation, and activation. This leads to enhanced cytotoxic T cell and NK cell-mediated killing of tumor cells. IL-2 has been used as an immunotherapeutic agent to boost endogenous anti-tumor immunity.
Approved indications
- Metastatic melanoma
- Metastatic renal cell carcinoma
Common side effects
- Capillary leak syndrome
- Hypotension
- Fever
- Chills
- Fatigue
- Nausea
- Thrombocytopenia
- Elevated liver enzymes
Key clinical trials
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1, PHASE2)
- A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (PHASE2)
- KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (PHASE1)
- Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (PHASE2)
- TREg Activation in the Treatment of the PELADE (Alopecia Areata) (PHASE3)
- Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients (PHASE2)
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IL2 CI brief — competitive landscape report
- IL2 updates RSS · CI watch RSS
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS portfolio CI